The purpose of this pilot study is to assess feasibility and to examine whether oral
cannabinoids (capsules containing either Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD)
combined or CBD alone) are safe and well-tolerated in people living with HIV. Other aims are
to determine whether oral cannabinoids may reduce HIV-associated inflammation. An exploratory
objective is to determine whether oral cannabinoids may influence HIV persistence as well as
the gastrointestinal microbiome.
Phase:
Phase 2
Details
Lead Sponsor:
McGill University Health Center McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators:
Centre de Recherche du Centre Hospitalier de l'Université de Montréal CIHR Canadian HIV Trials Network Tilray Université du Québec a Montréal